Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05462860 · ClinicalTrials.gov registry record · NA

Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds

A NA study of Burns and Wound of Skin, sponsored by The Metis Foundation.

Recruiting
Registry status
NA
Development phase
21
Enrollment target
1
Study location

NCT05462860 is a NA study of Burns and Wound of Skin that is actively recruiting participants, run by The Metis Foundation. The registered enrollment target is 21 participants, below the 83-participant average among 36 other Burns trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05462860, a NA study of Burns and Wound of Skin, is actively recruiting participants, sponsored by The Metis Foundation.

RECRUITING
Registry status
NA
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the effect to which Suprathel® (Polymedics Innovations GmbH, Denkendorf, Germany) can reduce the need for grafting compared to Standard of Care (SoC). Furthermore, the study intends to evaluate if Suprathel® allows for a reduction of reduction of pain, infection, provider workload, scar development and costs compared to SoC.

Conditions Studied

Interventions

  • OTHER Suprathel®

Study Locations (1)

North Carolina

  • North Carolina Jaycee Burn Center - Chapel Hill

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2024-09-18
Est. Completion 2026-06-29
Phase NA

Sponsor

The Metis Foundation

8 total trials

What the Registry Record Tells You About NCT05462860

The ClinicalTrials.gov registry entry for NCT05462860 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 36 other Burns trials with a reported enrollment target (75% lower). The listed sponsor is The Metis Foundation, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Burns appearing as the primary indexed condition, and to 1 intervention - of which Suprathel® is the first listed.

NCT05462860 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05462860 about?

NCT05462860 is a clinical study titled "Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds". The purpose of this study is to determine the effect to which Suprathel® (Polymedics Innovations GmbH, Denkendorf, Germany) can reduce the need for grafting compared to Standard of Care (SoC). Furthermore, the study intends to evaluate if Suprathel® allows for a reduction of reduction of pain, infec...

What is the current status of trial NCT05462860?

This trial is currently recruiting. It is a NA study. The enrollment target is 21 participants. The study started on 2024-09-18. Estimated completion is 2026-06-29.

What conditions does trial NCT05462860 study?

This clinical trial studies the following conditions: Burns, Wound of Skin.

What interventions are being tested in trial NCT05462860?

The interventions under investigation include: Suprathel® (OTHER).

Who is sponsoring clinical trial NCT05462860?

This trial is sponsored by The Metis Foundation, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05462860 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Burns

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.